La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Blonder Tongue Laboratories Salute del bilancio

Salute finanziaria criteri di controllo 0/6

Dati insufficienti per determinare lo stato di salute di Blonder Tongue Laboratories

Informazioni chiave

n/a

Rapporto debito/patrimonio netto

n/a

Debito

Indice di copertura degli interessi	n/a
Contanti	n/a
Patrimonio netto	n/a
Totale passività	n/a
Totale attività	n/a

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Have Blonder Tongue Laboratories, Inc. (NYSEMKT:BDR) Insiders Been Selling Their Stock?

Dec 23

Analisi della posizione finanziaria

Passività a breve termine: Dati insufficienti per determinare se le attività a breve termine di BDRL coprono le sue passività a breve termine.

Passività a lungo termine: Dati insufficienti per determinare se le attività a breve termine di BDRL coprono le sue passività a lungo termine.

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: Dati insufficienti per calcolare il rapporto debito netto/patrimonio netto di BDRL per determinare se è soddisfacente.

Riduzione del debito: Dati insufficienti per determinare se il rapporto debito/patrimonio netto di BDRL si sia ridotto negli ultimi 5 anni.

Copertura del debito: Dati insufficienti per determinare se il debito di BDRL è ben coperto dal flusso di cassa operativo.

Copertura degli interessi: Dati insufficienti per determinare se i pagamenti degli interessi sul debito di BDRL siano ben coperti dall'EBIT.

Blonder Tongue Laboratories Salute del bilancio

Salute finanziaria criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

NYSE American to Suspend Trading Immediately in Blonder Tongue Laboratories

NYSE American to Commence Delisting Proceedings Against Blonder Tongue Laboratories

Blonder Tongue Laboratories Receives Non-Compliance Letter from NYSE American

NYSE Accepts Compliance Plan of Blonder Tongue Laboratories, Inc

Recent updates

Blonder Tongue Announces IP Failover Feature Added to NXG Video Delivery System

Blonder Tongue Laboratories, Inc. Announces the Retirement of Stephen K. Necessary from the Board

Blonder Tongue Laboratories, Inc. Announces President Changes

Blonder Tongue Laboratories, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Blonder Tongue Laboratories Announces Product Standardization with Tier One Broadband Cable Operator

Blonder Tongue Laboratories, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Blonder Tongue Laboratories, Inc.(OTCPK:BDRL) dropped from S&P TMI Index

NYSE American to Suspend Trading Immediately in Blonder Tongue Laboratories

Blonder Tongue Laboratories, Inc. Announces Furloughing Ronald V. Alterio, the Senior Vice President-Engineering and Chief Technology Officer

Blonder Tongue Laboratories, Inc. Announces Resignation of Anthony Bruno as BOD, Effective from May 25, 2022

Blonder Tongue Laboratories, Inc., Annual General Meeting, May 25, 2022

Blonder Tongue Laboratories, Inc. Announces Retirement of James H. Williams as Member of the Board of Director

NYSE American to Commence Delisting Proceedings Against Blonder Tongue Laboratories

Independent Director Rick Briggs has left the company

Independent Director recently sold US$102k worth of stock

Third quarter 2021 earnings released: US$0.016 loss per share (vs US$0.18 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS US$0.14 (vs US$0.12 loss in 2Q 2020)

Director recently sold US$74k worth of stock

First quarter 2021 earnings released: US$0.036 loss per share (vs US$0.21 loss in 1Q 2020)

Full year 2020 earnings released: US$0.76 loss per share (vs US$0.077 loss in FY 2019)

Independent Director recently sold US$77k worth of stock

Blonder Tongue Laboratories, Inc. announced that it has received $0.6 million in funding

New 90-day high: US$1.85

MD of Strategic Accounts & Director recently sold US$52k worth of stock

Have Blonder Tongue Laboratories, Inc. (NYSEMKT:BDR) Insiders Been Selling Their Stock?

Blonder Tongue Laboratories Receives Non-Compliance Letter from NYSE American

New 90-day high: US$1.75

Third quarter 2020 earnings released: US$0.18 loss per share

New 90-day high: US$1.50

NYSE Accepts Compliance Plan of Blonder Tongue Laboratories, Inc

New 90-day high - US$1.35

Earnings released

Blonder Tongue Laboratories, Inc. to Report Q2, 2020 Results on Aug 07, 2020

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Scoprire le aziende sane